SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal ...
Use of Agilent’s custom microarrays in the SOMAscan® assay will help drive biomarker discovery efforts as well as novel diagnostics and accelerated pharmaceutical development SANTA CLARA, Calif. & ...
OXFORD, England--(BUSINESS WIRE)-- Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D ...
Agilent Technologies Inc. has announced the extension of its technology access program to National Cancer Institute (NCI) extramural researchers. The NCI funds approximately 4,500 research grants a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback